A phase II trial of the intranasal respiratory syncytial virus (RSV) vaccine, SynGEM, in patients with RSV infection
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Respiratory syncytial virus vaccine-Mucosis (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 07 Nov 2016 According to Mucosis B.V media release, this trial is due to start in mid-2017.
- 22 Jan 2016 New trial record
- 20 Jan 2016 The company plans to advance the Investigational Medicinal Product Dossier (IMPD) submission materials for clinical trial approval in 2016, according to a Mucosis media release.